文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

血清前蛋白转化酶枯草溶菌素 9 与 2 型糖尿病患者的血管疾病。

Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients.

机构信息

Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy.

First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.

出版信息

Eur J Clin Invest. 2023 Mar;53(3):e13900. doi: 10.1111/eci.13900. Epub 2022 Nov 17.


DOI:10.1111/eci.13900
PMID:36346620
Abstract

BACKGROUND: Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating the degradation of low-density lipoprotein receptor as well as different inflammatory pathways. Considering the important prognostic role of arterial stiffness in cardiovascular disease (CVD), the aim of the study is to investigate the correlation between PCSK9 levels and arterial stiffness in a cohort of diabetic patients, without previous CV events. METHODS: This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-femoral pulse wave velocity (PWV). RESULTS: Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrinogen and white blood cells (WBC) and a reduction in estimated glomerular filtration rate (e-GFR). Patients with higher levels of PCSK9 presented increased systolic, diastolic blood pressure, pulse pressure and PWV. PWV was significantly and directly correlated with PCSK9, fibrinogen, age, BMI and PP, and indirectly correlated with diet, lifestyle and e-GFR. Serum PCSK9 was the major predictor of PWV, justifying a 16.9% of its variation. CONCLUSION: Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological medications. Serum PCSK9 could be a useful biomarker for CV risk stratification in diabetic subjects.

摘要

背景:前蛋白转化酶枯草溶菌素 9(PCSK9)水平被认为是一种新型的动脉粥样硬化生物标志物。PCSK9 通过调节低密度脂蛋白受体的降解以及不同的炎症途径,在动脉粥样硬化的发病机制中发挥重要作用。考虑到动脉僵硬度在心血管疾病(CVD)中的重要预后作用,本研究旨在探讨在无先前心血管事件的 2 型糖尿病患者队列中,PCSK9 水平与动脉僵硬度之间的相关性。

方法:本横断面分析纳入了 401 名白种人 2 型糖尿病患者。通过 ELISA 试验测量 PCSK9 水平,通过测量颈股脉搏波速度(PWV)来评估动脉僵硬度。

结果:根据 PCSK9 值的增加,患者被分为三个三分位组。从第 1 到第 3 三分位,高敏 C 反应蛋白(hs-CRP)、纤维蛋白原和白细胞(WBC)显著增加,估算肾小球滤过率(e-GFR)降低。PCSK9 水平较高的患者收缩压、舒张压、脉压和 PWV 均升高。PWV 与 PCSK9、纤维蛋白原、年龄、BMI 和 PP 呈显著正相关,与饮食、生活方式和 e-GFR 呈间接相关。血清 PCSK9 是 PWV 的主要预测因子,可解释其 16.9%的变异性。

结论:本研究表明,在无先前心血管事件的 2 型糖尿病患者中,循环 PCSK9 水平与 PWV 密切相关,即使在调整了已知的心血管危险因素和药物治疗后也是如此。血清 PCSK9 可能是糖尿病患者心血管风险分层的有用生物标志物。

相似文献

[1]
Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients.

Eur J Clin Invest. 2023-3

[2]
Association of serum proprotein convertase subtilisin/kexin type 9 with early atherosclerosis in newly diagnosed type 2 diabetes mellitus.

Nutr Metab Cardiovasc Dis. 2019-4-24

[3]
Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.

J Am Heart Assoc. 2017-5-3

[4]
Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey.

J Periodontal Res. 2018-3-8

[5]
Predictors of functional and morphological arterial wall properties in coronary artery disease patients with increased lipoprotein (a) levels before and after treatment with proprotein convertase subtilisin-kexin type 9 inhibitors.

Cardiovasc Ultrasound. 2023-8-14

[6]
Plasma PCSK9 levels are unrelated to arterial stiffness in a community-based, 4.8-year prospective study.

J Hum Hypertens. 2017-11

[7]
PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy.

Biomolecules. 2022-4-9

[8]
Positive correlation of plasma PCSK9 levels with HbA1c in patients with type 2 diabetes.

Diabetes Metab Res Rev. 2015-10-28

[9]
Circulating PCSK9 levels and 2-hPG are positively correlated in metabolic diseases in a Chinese Han population.

Lipids Health Dis. 2018-1-17

[10]
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes.

Diabetes Obes Metab. 2018-1-14

引用本文的文献

[1]
Proprotein convertase subtilisin/kexin type 9: a promising marker of cardiovascular risk in post-menopausal diabetic women in primary prevention.

Front Med (Lausanne). 2025-3-12

[2]
The correlation between proprotein convertase subtilisin/kexin type 9 and adiponectin in the progression from prediabetes to type 2 diabetes mellitus.

Sci Rep. 2025-3-12

[3]
Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus.

Diabetol Metab Syndr. 2023-12-20

[4]
PCSK9 as an Atherothrombotic Risk Factor.

Int J Mol Sci. 2023-1-19

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索